Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase

What Was Tested

This randomized controlled trial paper looks at Insulin (regular human) and Insulin Lispro.

This study was undertaken to compare the postprandial glycemic response of patients with type 2 diabetes mellitus (T2DM) administered insulin lispro with and without recombinant human hyaluronidase (rHuPH20) and regular human insulin (RHI) with rHuPH20.

Who Took Part

The study group was 21 patients.

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

Because people in this Insulin (regular human) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Insulin (regular human).

Each person switched between Insulin (regular human) and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Hyaluronoglucosaminidase, Hypoglycemic Agents, Insulin Lispro, Insulin, Regular, Human and Postprandial Period.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin (regular human) and Insulin Lispro in 21 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin (regular human) compound page and the Insulin Lispro compound page.